ContractStock Option Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Delaware
THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
Consulting AgreementConsulting Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (“Agreement”) is effective as of February 1, 2018 by and between NeuroBo Pharmaceuticals, Inc. (“NeuroBo”), a Massachusetts corporation with its principal place of business at 177 Huntington Avenue, Suite 1732, Boston, MA 02115 (email — jkang@jkbiopharma.com) and vZenium LLC (“Consultant”), a Massachusetts limited liability company, owned and managed entirely by Mark Versavel, MD, PhD, MBA with a principal place of business at 47 Marathon Street, Arlington, MA 02474 (email - mark.versavel@vzenium.com).
MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations
This MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of September 28, 2018 (“Effective Date”) by and between:
FOURTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Agreement”) is made as of May 30, 2019 by and among (i) NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) the Persons whose names are set forth under the heading “Initial Holders” on Schedule A hereto (the “Initial Holders”), (iii) the Persons whose names are set forth under the heading “Investors” on Schedule A hereto (comprised of the Series A Investors and the Series B Investors, each as defined below, the “Investors”), (iv) Dong-A ST Co., Ltd (“Dong-A”) and (v) each other Person who shall, after the date hereof, acquire shares of Capital Stock and join in and become a party to this Agreement by executing and delivering a Joinder Agreement (the “Subsequent Holders,” and collectively with the Initial Holders, the Investors and Dong-A, the “Holders”). This Agreement replaces all prior versions including the Third Amended and Restated Stockholders’ Agreement dated April 9, 2018, signed by the Init
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...Acquisition Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
ACQUISITION AGREEMENT, dated as of January , 2018 (“Effective Date”), between Dong-A ST Co., Ltd., a Republic of Korea company having its principal place of business at 64 Cheonho-daero, Dongdaemun-gu, Seoul 02587, Republic of Korea (“Dong-A”) and NeuroBo Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 177 Huntington Avenue, Suite 1732, Boston, MA 02115, U.S.A. (“NeuroBo”).
LICENSE AGREEMENT (DA-9801) Between DONG-A ST CO., LTD. And NEUROBO PHARMACEUTICALS, INC. Dated: January 18, 2018License Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
LICENSE AGREEMENT, dated as of January 18, 2018 (“Signing Date”), between Dong-A ST Co., Ltd., a Republic of Korea company having its principal place of business at 64 Cheonho-daero, Dongdaemun-gu, Seoul 02587, Republic of Korea (“Dong-A”) and NeuroBo Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 177 Huntington Avenue, Suite 1732, Boston, MA 02115, U.S.A. (“NeuroBo”).
Consulting AgreementConsulting Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (“Agreement”) is effective as of February 1, 2018 by and between NeuroBo Pharmaceuticals, Inc. (“NeuroBo”), a Massachusetts corporation with its principal place of business at 177 Huntington Avenue, Suite 1732, Boston, MA 02115 (email — jkang@jkbiopharma.com) and Healthcare Capital LLC (“Consultant”), a Massachusetts limited liability company, owned and managed entirely by John L. Brooks III with a principal place of business at 3 Tannery Drive, Medfield, MA 02052 (email - jlbrooksiii@gmail.com).
Pangyo TechnoValley 2 The Knowledge Industrial Center (Corporate Growth Center F1) Lease AgreementGemphire Therapeutics Inc. • September 3rd, 2019 • Pharmaceutical preparations
(2 lots including 293-dab Siheung-dong Soojung-gu, Sungnam, Gyeonggi Province, Changup-ro 42 Soojung-gu, Sungnam, Gyeonggi Province)
Long Term Lease Agreement (NeuroBo Co., Ltd.) Room Number: 707, 53.22 m2 Invest Korea PlazaLong Term Lease Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations
This Long Term Lease Agreement (hereinafter referred to as this “Agreement”) is entered into between Invest Korea Plaza (hereinafter referred to as the “Lessor”), and NeuroBo Co., Ltd. (hereinafter referred to as the “Lessee”).
Independent Contractor AgreementIndependent Contractor Agreement • September 3rd, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Independent Contractor Agreement (“Agreement”) is effective as of March 1, 2019 by and between NeuroBo Pharmaceuticals, Inc. (“NeuroBo”), a Massachusetts corporation with its principal place of business at 177 Huntington Avenue, Suite 1700, Boston, MA 02115 (email — jlbrooksiii@neurobopharma.com) and Therabo PLLC, a Massachusetts professional limited liability company, owned and managed by Roy Freeman (together, the “Consultant”), with a principal place of business at 256 Summit Ave., Brookline, MA 02446 (email — royfreeman@gmail.com).
